Core Insights - CHC Navigation (CHCNAV) has launched the RS7, a handheld SLAM scanning solution aimed at enhancing BIM documentation, indoor surveying, renovation planning, and complex spatial analysis [1][9] Group 1: Product Features - The RS7 integrates a next-generation LiDAR scanner that can measure up to 1.15 million points per second, with a wide field of view of 360° x 189°, allowing for comprehensive coverage and reducing the need for repeated passes in complex environments [2] - It includes a high precision inertial measurement unit with bias stability better than 0.5°/h, ensuring stable motion estimation and consistent point cloud quality in challenging mobile workflows [2] - The RS7 supports high fidelity visualization with dual 12-megapixel cameras optimized for low light, utilizing the CHCNAV HPGS 2.0 engine for photorealistic scene rendering through 3D Gaussian Splatting outputs [4] Group 2: Workflow Integration - The RS7 is supported by CHCNAV's software ecosystem, facilitating an integrated workflow from scan setup to data review and post-processing, which can reduce turnaround time and lower technical barriers for users [3] - The "Cloud + Terminal" workflow allows for centralized project and data management, enabling automated processing of field datasets to generate deliverables like registered point clouds and mesh models [3] Group 3: Company Overview - CHC Navigation specializes in mapping, navigation, and positioning technologies, serving industries such as geospatial, agriculture, construction, and autonomy [5] - The company operates in over 140 countries and employs more than 2,200 professionals globally, focusing on integrated solutions that enhance productivity and efficiency in spatial data management [5]

Core Viewpoint - Alkane Resources Limited has announced significant exploration results and drilling activities aimed at expanding the underground resources at its Tomingley Gold Operations in New South Wales, indicating strong potential for resource expansion both near the mine and regionally [1][4]. Exploration Results - The exploration at Tomingley has revealed extensions to existing deposits and new areas of mineralization, with ongoing drilling demonstrating substantial resource expansion potential [4]. - Recent drilling at the Roswell deposit has confirmed high-grade gold zones, with notable intercepts including 5.9 meters grading 31.0 g/t Au and 17.4 meters grading 4.30 g/t Au [6][16][19]. - At the El Paso prospect, significant results include 17 meters grading 4.02 g/t Au, with high-grade intervals of 14.1 g/t Au and 77.5 g/t Au [22]. Resource Estimates - The Roswell underground resources are estimated at 5.5 million tonnes grading 2.6 g/t Au, totaling approximately 476,000 ounces of gold [11][30]. - The total mineral resources at Tomingley as of June 2025 amount to 19.234 million tonnes with an average grade of 2.2 g/t Au, equating to 1,358,000 ounces of gold [30][33]. Development and Future Plans - The company plans to continue its exploration drilling at the Wyoming Three deposit and the northern extensions of the main andesite host at Caloma, with a second phase of drilling expected to be completed by Q3 2026 [27][28]. - Further exploration efforts will focus on identifying new targets outside the Tomingley Gold Operations, including additional drilling at the Westray prospect [21][26]. Operational Overview - The Tomingley Gold Operations include both open pit and underground mining developments, with a processing facility operating since 2014, located approximately 50 kilometers southwest of Dubbo [5][46]. - Alkane Resources operates three mines across Australia and Sweden, with ongoing regional exploration aimed at growing resources at all operations [48].

Core Insights - Supernus Pharmaceuticals, Inc. is actively participating in multiple investor conferences in March 2026, showcasing its commitment to engaging with investors and stakeholders in the biopharmaceutical sector [1][2][3]. Conference Participation - The company will attend the TD Cowen 46th Annual Health Care Conference on March 2, 2026, with a fireside chat scheduled for 2:30 p.m. ET in Boston, Massachusetts [1]. - Supernus will also participate in the Jefferies Biotech on the Beach Summit on March 10, 2026, held in Miami Beach, Florida [2]. - Additionally, the company is set to present at the Barclays 28th Annual Global Healthcare Conference on March 11, 2026, with a fireside chat at 2:00 p.m. ET in Miami Beach, Florida [3]. Webcast Availability - Live audio webcasts of the TD Cowen and Barclays Conference presentations will be accessible on the Supernus Pharmaceuticals website, with archived replays available for 60 days post-conference [4]. Company Overview - Supernus Pharmaceuticals focuses on developing and commercializing products for the treatment of central nervous system (CNS) diseases, indicating a specialized niche within the biopharmaceutical industry [5]. - The company's neuroscience portfolio includes approved treatments for various conditions such as ADHD, Parkinson's disease-related dyskinesia, postpartum depression, epilepsy, and migraine, among others [6].

Core Viewpoint - The FDA has placed a partial clinical hold on MacroGenics' Phase 2 LINNET study of lorigerlimab, affecting new patient enrollment due to recent safety events [1][2]. Group 1: FDA Clinical Hold - The partial clinical hold was initiated after MacroGenics notified the FDA of a temporary pause in enrollment due to safety events involving four patients, including Grade 4 thrombocytopenia (2 patients), Grade 4 myocarditis (1 patient), and Grade 4 neutropenia with concurrent septic shock leading to a Grade 5 event (1 patient) [2]. - No new patients will be enrolled in the LINNET study until the hold is lifted, but current participants can continue receiving the study drug [1][2]. Group 2: LINNET Study Details - The LINNET study evaluates lorigerlimab, a bispecific DART® molecule targeting PD-1 and CTLA-4, as monotherapy in patients with platinum-resistant ovarian cancer (PROC) and clear cell gynecologic cancer (CCGC) [3]. - The study is designed as a Simon two-stage trial, initially enrolling approximately 20 patients, with the potential to expand to an additional 20 patients if a predefined activity threshold is met [3]. - The primary endpoint of the study is the objective response rate (ORR), with multiple secondary endpoints [3]. Group 3: Company Overview - MacroGenics is a biopharmaceutical company focused on developing innovative monoclonal antibody-based therapeutics for cancer treatment [4]. - The company generates its pipeline from proprietary next-generation antibody-based technology platforms, enabling strategic collaborations with global pharmaceutical and biotechnology companies [4].

Record 4Q and Full Year Performance at Work Truck Solutions; Record Parts & Accessories Sales at Work Truck Attachments Full Year 2025 Highlights* Consolidated Net Sales increased 15.4% to $656.1 millionWinter weather drove robust Parts & Accessories sales across the company, particularly in 4QDelivered Diluted Earnings per Share (EPS) of $1.96; Adjusted Diluted EPS increased 52.0% to $2.24Both segments produced Net Sales and Adjusted EBITDA growth for both 4Q and Full Year 2025 Acquired Venco Venturo in 4Q ...

Company to Transfer Listing of Its Securities to New York Stock ExchangeHAUPPAUGE, N.Y., Feb. 23, 2026 (GLOBE NEWSWIRE) -- Dime Community Bancshares, Inc. (the “Company” or “Dime”), the parent company of Dime Community Bank (the “Bank”) today announced that, subject to shareholder approval, it will change its name to “Dime Commercial Bancshares, Inc.”. The Bank’s name will change to “Dime Commercial Bank”. These changes will be effective soon after the Annual Shareholder Meeting (May 28, 2026), where there ...

Core Viewpoint - Creatd, Inc. will implement a 20:1 reverse stock split of its common stock effective February 24, 2026, to meet national exchange listing requirements [1][2][7] Group 1: Reverse Stock Split Details - The reverse stock split will reduce the number of issued and outstanding shares on a 1-for-20 basis, with the stock symbol changing to $CRTDD for 20 business days starting February 24, 2026, before resuming as $CRTD [2][3] - The reverse stock split was approved by the Company's Board of Directors and Shareholders, and will be executed through FINRA's corporate action process [3][7] - The split will proportionally increase the per-share trading price while maintaining each shareholder's relative ownership interest, with no fractional shares issued [4][7] Group 2: Shareholder Impact - Shareholders holding shares in brokerage accounts or in book-entry form will not need to take any action, as the adjustment will be automatically reflected in their accounts [5]

Core Viewpoint - The successful merger of Alm. Brand and Codan has led to the resignation of CEO Rasmus Werner Nielsen, with Andreas Ruben Madsen appointed as the new CEO effective from March 1, 2026 [1] Group Management Changes - Andreas Ruben Madsen has been with Alm. Brand for ten years, serving as CFO for the last six years and Deputy CEO since March 2025 [1] - The new Group Executive Management team will consist of Andreas Ruben Madsen (CEO), Camilla Amstrup (CCO), and Bo Krag Esbensen (COO) starting from March 1, 2026 [1] Leadership Transition - Chairman Jais Valeur highlighted Madsen's crucial role in transforming Alm. Brand into a focused Danish non-life insurer and his involvement in developing the group's strategy for the next three years [1] - Rasmus Werner Nielsen expressed pride in his contributions to Alm. Brand and indicated that the completion of the strategy period and the achievement of ambitious targets for 2025 made it the right time for him to step down [1]

Expansion in 2026 Forecasted to Exceed 5,000 Retail Outlets Nationwide as Consumers Demonstrate Interest in VLN® Brands VLN® Remains the Only FDA-Authorized Combustible Cigarette Designed to Reduce Nicotine Consumption MOCKSVILLE, N.C., Feb. 23, 2026 (GLOBE NEWSWIRE) -- 22nd Century Group, Inc. (Nasdaq: XXII), a tobacco products company focused on reducing the harms of smoking through nicotine reduction, today announced continued early sales momentum for its VLN® low nicotine cigarette products in the U.S. ...

Favorable safety and tolerability profile with no Grade 3 or greater treatment-related adverse events Company expects to complete enrollment of the BCG-Unresponsive cohort of the ADVANCED-2 trial in 2H 2026 Company to host conference call and webcast tomorrow at 8:00 a.m. ET NEW YORK, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Protara Therapeutics, Inc. (Nasdaq: TARA), a clinical-stage company developing transformative therapies for the treatment of cancer and rare diseases, today announced updated interim results ...